2d illustrations and photos
CG Oncology (CGON) has filed to raise approximately $100M through an initial public offering.
The biotech company didn’t specify any terms in its SEC filing, but indicated in a filing fee schedule that it was interested in raising around $100M, a number that is likely a placeholder and subject to change.
CG Oncology hopes to list its shares on Nasdaq under the symbol CGON. Underwriters include Morgan Stanley, Goldman Sachs, Cantor and LifeSci Capital.
Based in California, CG Oncology has been developing a bladder-sparing therapy for patients with bladder cancer. The company’s lead drug candidate, cretostimogene, is in Phase 3 testing.
More on CG Oncology, Inc.
Source link
